Descriptive Study on MRI Contrast of Acute Cerebral Hemorrhage in Different Microangiopathies

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NĪMES · Jan 13, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how certain imaging techniques, specifically MRI with a contrast agent called gadolinium, can help doctors understand acute cerebral hemorrhages better. Cerebral hemorrhages occur when there is bleeding in the brain, and while they are less common than strokes, they can be very serious and currently have no specific treatment. The researchers want to look for a specific sign, known as the "spot sign," on MRI scans that may indicate a higher risk of the bleeding worsening. By identifying these signs, they hope to find groups of patients who could benefit from future treatments.

To be eligible for this trial, patients must be between the ages of 65 and 74 and have an acute cerebral hematoma, which is a type of brain bleed, related to conditions like cerebral amyloid angiopathy or hypertension. They should also have had a follow-up CT scan to monitor their condition. Participants will have their MRI scans analyzed to help improve understanding of their condition and guide future research. It’s important to note that patients must agree to participate in the study, as those who refuse will not be included.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with acute cerebral hematomas from existing databases of cerebral amyloid angiopathy and hypertensive microangiopathy managed at Nîmes University Hospital;
• • Patients who have undergone a follow-up cerebral CT scan in the event of worsening or for follow-up.
• Exclusion Criteria:
• • Patient refusing to participate